Connect with us

National

Moderna Sinks on AstraZeneca Covid-19 Vaccine Progress, JPMorgan Downgrade – Investing.com

Moderna Sinks on AstraZeneca Covid-19 Vaccine Progress, JPMorgan Downgrade

Published

on

post featured image

By Christiana Sciaudone
Investing.com — Moderna (NASDAQ:MRNA) dropped 14% after AstraZeneca (NYSE:AZN) and Oxford University said their vaccine candidate showed promise.
The AstraZeneca-Oxford vaccine, AZD1222, is safe and produced an immune response in early-stage clinical trials in healthy volunteers, Reuters reported, citing data from The Lancet. No serious side effects were reported.
JPMorgan (NYSE:JPM) downgraded Moderna, which is working on a separate vaccine candidate, today on a hig…

Click here to view the original article.